home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc. From 11/04/25

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
NRX:CC NRX:CC Quote NRX:CC Short NRX:CC News NRX:CC Articles NRX:CC Message Board
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - 4 Best-performing Canadian Pharma Stocks of 2025

2025-11-04 04:15:00 ET From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies su...
NRX:CC - NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) announced today that it has been accepted to the BioFab Startup Lab , part of the Advanced Regenerati...

NRX:CC - NurExone Invited Presenter at Precision EV Forum in Cambridge, UK

TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina Sarel, Director o...

NRX:CC - NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) a biopharmaceutical company developing exosome-based regenerative therapies, announced new preclinic...
NRX:CC - NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana

TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that...

NRX:CC - NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing

TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to p...

NRX:CC - NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness

TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that...
NRX:CC - NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous sys...

NRX:CC - Expected Canadian Company Earnings on Tuesday, August 26th, 2025

Backstageplay Inc. (BP.H:CA) is expected to report for quarter end 2025-06-30 Coloured Ties Capital Inc. (TIE:CA) is expected to report for quarter end 2025-06-30 PetroFrontier Corp. (PFC:CA) is expected to report for quarter end 2025-06-30 Belgravia Capital Intl (BLGV:CNX) is expecte...

NRX:CC - Expected earnings - NurExone Biologic Inc.

NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q2 2025
Previous 10 Next 10